Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

25 oct 2017 7:00 a.m. - 27 oct 2017 3:00 p.m.

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Session 2C: Cardiovascular/Metabolic Diseases

Session Chair(s)

Peter  Wijngaard, PhD

Peter Wijngaard, PhD

Executive Vice President and Chief Development Officer

The Medicines Company, United States

Review progress made in the clinical development of RNA therapeutics in the cardiovascular and metabolic therapeutic areas. The targets and applications range from Factor XI antagonism in the coagulation pathway using antisense oligonucleotides to the inhibition of PCSK9 synthesis via RNA interference and GalNAc conjugation to reduce cardiovascular risk factors.

Learning Objective : At the conclusion of this session, participants should be able to:

  • Identify accomplishments and challenges in the clinical development of oligonucleotide-based therapeutic drugs for Cardiovascular/Metabolic diseases
  • Recognize the achievements made in the field to date and be able to share the therapeutic potential with potential customers (patients, prescribers, payors) that oligonucleotides possess in (large) cardiovascular/metabolic indications

Speaker(s)

Elena  Braithwaite, PhD

Session Co-Chair

Elena Braithwaite, PhD

FDA, United States

Toxicologist

Sanjay  Bhanot, MD, PhD

Antisense Reduction of FXI for Thromboprophylaxis: A Novel Therapeutic Approach

Sanjay Bhanot, MD, PhD

Ionis Pharmaceuticals, Inc., United States

Vice President, Metabolic Diseases, Research & Development

Louis  St.L. O'Dea

Volanesorsen: Targeting ApoC-III for Treatment of Patients with Familial Chylomicronemia Syndrome (FCS)

Louis St.L. O'Dea

AKCEA Therapeutics, United States

Executive Vice President, Chief Medical Officer and Head, Regulatory Affairs

Peter  Wijngaard, PhD

PCSK9 Synthesis Inhibition: siRNA Therapeutic for Large Indications

Peter Wijngaard, PhD

The Medicines Company, United States

Executive Vice President and Chief Development Officer

  Panel Discussion

Panel Discussion

All Session Speakers, United States

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.